FusoGen

FusoGen Pharmaceuticals was a biotechnology company focused on the discovery and development of a new class of antiviral drugs known as fusion inhibitors. The company's primary research centered on preventing the entry of HIV into healthy cells by targeting the gp41 protein, a critical component of the viral fusion process. FusoGen's proprietary technology platform enabled the design of potent peptide-based inhibitors that blocked the conformational changes required for viral-cell membrane fusion. The company was notably acquired by Trimeris in 2001, consolidating the intellectual property and development efforts for the first-in-class HIV fusion inhibitor, enfuvirtide.